ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial / Rugo, Hope S; Im, Seock-Ah; Cardoso, Fatima; Cortés, Javier; Curigliano, Giuseppe; Musolino, Antonino; Pegram, Mark D; Wright, Gail S; Saura, Cristina; Escrivá-de-Romaní, Santiago; De Laurentiis, Michelino; Levy, Christelle; Brown-Glaberman, Ursa; Ferrero, Jean-Marc; de Boer, Maaike; Kim, Sung-Bae; Petráková, Katarína; Yardley, Denise A; Freedman, Orit; Jakobsen, Erik H; Kaufman, Bella; Yerushalmi, Rinat; Fasching, Peter A; Nordstrom, Jeffrey L; Bonvini, Ezio; Koenig, Scott; Edlich, Sutton; Hong, Shengyan; Rock, Edwin P; Gradishar, William J. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - (2021). [10.1001/jamaoncol.2020.7932]

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Musolino, Antonino;
2021-01-01

Abstract

ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial / Rugo, Hope S; Im, Seock-Ah; Cardoso, Fatima; Cortés, Javier; Curigliano, Giuseppe; Musolino, Antonino; Pegram, Mark D; Wright, Gail S; Saura, Cristina; Escrivá-de-Romaní, Santiago; De Laurentiis, Michelino; Levy, Christelle; Brown-Glaberman, Ursa; Ferrero, Jean-Marc; de Boer, Maaike; Kim, Sung-Bae; Petráková, Katarína; Yardley, Denise A; Freedman, Orit; Jakobsen, Erik H; Kaufman, Bella; Yerushalmi, Rinat; Fasching, Peter A; Nordstrom, Jeffrey L; Bonvini, Ezio; Koenig, Scott; Edlich, Sutton; Hong, Shengyan; Rock, Edwin P; Gradishar, William J. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - (2021). [10.1001/jamaoncol.2020.7932]
File in questo prodotto:
File Dimensione Formato  
jamaoncology_rugo_2021_oi_200114_1611083625.00813 (1).pdf

accesso aperto

Tipologia: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 453.38 kB
Formato Adobe PDF
453.38 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2886911
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 121
  • ???jsp.display-item.citation.isi??? 121
social impact